My recommendation for IDEXX Laboratories, Inc. ( IDXX ) is a buy rating. My thesis is simple. The COVID surge in pet ownership has permanently raised the baseline for demand in veterinary diagnostics, and IDXX is best positioned toI focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to ...

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to associated risks and volatility [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Idexx Laboratories (IDXX) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth seen as indicative of strong future prospects [4] - Idexx's historical EPS growth rate is 12.5%, with projected growth for the current year at 14.1%, surpassing the industry average of 13.6% [5] Group 3: Cash Flow Growth - High cash flow growth is essential for growth-oriented companies, allowing them to fund new projects without external financing [6] - Idexx's year-over-year cash flow growth is currently 6%, significantly better than the industry average of -0.8% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 14.6%, compared to the industry average of 6.7% [7] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions are correlated with stock price movements [8] - Idexx's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 0.1% over the past month [8] Group 5: Overall Assessment - Idexx holds a Zacks Rank of 2 and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has atai Life Sciences N.V. (ATAI) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.atai Life Sciences N.V. is a member of our Medical group, which includes 997 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the str ...

Core Insights - IDEXX Laboratories, Inc. has launched the Catalyst® Cortisol Test, which provides real-time quantitative cortisol measurements to assist in diagnosing Addison's disease and managing Cushing's syndrome in dogs [1][4][5] Group 1: Product Launch and Features - The Catalyst Cortisol Test is the third expansion of the Catalyst platform within a year, enhancing diagnostic capabilities for veterinary practices [1][4] - This test allows for immediate diagnosis or ruling out of Addison's disease and Cushing's syndrome during patient visits, facilitating timely treatment [4][6] - The test will be available in the U.S. and Canada by the end of July 2025, with a global rollout expected to start in Q3 2025 [6] Group 2: Importance of the Test - Addison's disease is challenging to diagnose due to its nonspecific symptoms, making early detection crucial for effective treatment [3] - Cushing's syndrome, prevalent in older dogs, requires long-term management, and untreated cases can severely impact quality of life [3] - The Catalyst Cortisol Test improves long-term care for dogs with Cushing's syndrome by enabling tailored treatment adjustments [4] Group 3: Company Vision and Commitment - IDEXX emphasizes its commitment to advancing veterinary care through innovative solutions that enhance clinical insights and care delivery [5][7] - The test integrates with existing IDEXX systems, providing real-time interpretive guidance to streamline workflows for veterinary teams [8]

Core Viewpoint - IDEXX Laboratories, Inc. (NASDAQ: IDXX) has seen a stock price increase of over 22% since being upgraded to a Buy rating in March 2025, despite a decline in U.S. clinical visits [1]. Company Performance - The company delivered strong quarterly results, indicating resilience in its operations despite external challenges [1]. Investment Strategy - The investment approach focuses on fundamental, bottom-up analysis with an emphasis on long-term quality growth, targeting companies in niche markets with strong growth potential and reasonable valuations [1]. - The portfolio typically consists of 15-20 stocks, emphasizing diversification, risk management, macro-driven sector weights, and disciplined trading [1].

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Idexx Laboratories (IDXX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Idexx Laboratories is one of 1001 individual stocks in the Medical sect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware ...

IDEXX Q1 2024 Earnings Highlights (NASDAQ: IDXX) IDEXX Q1 2025 Earnings Highlights (NASDAQ: IDXX) | Revenue | | | Operating | | | Diluted | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | Profit | | | Earnings Per Share | | | | | $998M | | | $317M | | | $2.96 | | | | | Reported growth: | +4% | 31.7% | of Revenue | | | | | | | | | | | | | | Reported growth: | | +5% | | | Organic growth: | +5% | YoY change in basis points: | | | | | | | | | CAG Diagnostics Recurring | | Reported | ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.37%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.40 per share when it actually produced earnings of $2.62, delivering a surprise of 9.17%.Over t ...

IDEXX Laboratories (IDXX) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO and TreasurerJay Mazelsky - President and CEOMichael Ryskin - Managing DirectorKatarina Markovic - Executive DirectorJonathan Block - Managing DirectorDaniel Clark - VP - Equity Research Conference Call Participants Erin Wright - AnalystBrandon Vazquez - Research AnalystDavid Westenberg - Managing Director & Senior Research AnalystNavann Ty Dietschi - Lead Analyst Operator Good mo ...